Chimeric antigen receptor

Chimeric antigen receptor

A lab engineered receptor designed to bind certain proteins, such as surface proteins on cancer cells, that is added to immune cells for immunotherapy strategies such as directing T cells to fight cancer.

All edits by  Jude Gomila 

Edits on 19 Mar, 2019
Jude Gomila
Jude Gomila edited on 19 Mar, 2019
Edits made to:
Article (+15/-14 characters)
Article

CARs are recombinant protein molecules that cause cell activation upon encountering the target antigen. The antigen-recognition domain of a CAR is usually derived from monoclonal antibody sequences.Cellsequences. Cell therapies being used or in development for treating cancer or autoimmune diseases use T cells or regulatory T cells (Tregs) respectively. CAR-T cells are engineered T cells and CAR-Treg cells are engineered Tregs.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar, 2019
Edits made to:
Article (+14/-14 characters)
Article

CARs are recombinant protein molecules that cause cell activation upon encountering the target antigen. The antigen-recognition domain of a CAR is usually derived from monoclonal antibody sequences.Cell therapiesCell therapies being used or in development for treating cancer or autoimmune diseases use T cells or regulatory T cells (Tregs) respectively. CAR-T cells are engineered T cells and CAR-Treg cells are engineered Tregs.

Edits on 2 Mar, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 2 Mar, 2019
Edits made to:
Article (+12/-12 characters)
Article

The first CAR-T treatment was approved by the FDA in 2017 and there are several in clinical trials. CAR-T has been successful in treating hematological malignancies. US FDA approved CAR-T therapies include CD19-targeting CAR-T cells, tisagenlecleucel (Kymriah-Novartis) in leukemia and lymphoma and axicabtagene ciloleucel (Yescarta – Kite) in lymphoma. Challenges to CAR-T including toxicity due to attacking non-cancer cells, "clonal escape" due to diversity of cancer cellscancer cells, dosing, immunosuppression (turning off) of the T-cells, and T-cell apoptosis (cell death).

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 2 Mar, 2019
Edits made to:
Article (+11/-11 characters)
Article

Allogeneic or universal cell therapy products, also called off-the-shelf cell therapy products would allow a broader implementation of these cell therapies. One method being researched is to derive natural killer (NK) cells from induced pluripotent stem cells (iPS) cells and engineer iPS cell-derived NK cells to target and kill cancer cellcancer cell similarly to CAR-T cells.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 2 Mar, 2019
Edits made to:
Article (+10/-10 characters)
Article

The first CAR-T treatment was approved by the FDA in 2017 and there are several in clinical trials. CAR-T has been successful in treating hematological malignancies. US FDA approved CAR-T therapies include CD19-targeting CAR-T cells, tisagenlecleucel (Kymriah-Novartis) in leukemia and lymphoma and axicabtagene ciloleucel (Yescarta – Kite) in lymphoma. Challenges to CAR-T including toxicity due to attacking non-cancer cells, "clonal escape" due to diversity of cancer cells, dosing, immunosuppression (turning off) of the T-cells, and T-cell apoptosis (cell deathcell death).

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.